Skip to content

Peptide library / Brain & sleep / Cibinetide

In clinical trialsBrain & sleep

Cibinetide

An 11 amino acid peptide derived from erythropoietin that calms inflammation without raising red blood cells.

Body system
Brain & sleep
Status
In clinical trials
Strongest evidence
Small human studies
Also known as
ARA-290

Effects studied or claimed

What it is used or promoted for, and where each effect has actually been seen

  • Small fiber neuropathy in sarcoidosisSmall human studies
  • Neuropathic pain in diabetesSmall human studies

How it is thought to work

Cibinetide activates the innate repair receptor, a combination of the erythropoietin and beta common receptors, promoting nerve and tissue repair.

What the evidence shows

Small phase 2 trials reported improved nerve fiber density and symptom scores. Larger trials are needed.

Safety and unknowns

Injection site reactions and mild adverse effects were reported.

Regulatory status

Not approved. Studied in phase 2 trials.

Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.

More in Brain & sleep

General information, not medical advice. Do not buy or inject unregulated peptides.